Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy

Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 2...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 9; no. 11; p. 1354
Main Authors Loconsole, Daniela, Centrone, Francesca, Morcavallo, Caterina, Campanella, Silvia, Accogli, Marisa, Sallustio, Anna, Peccarisi, Davide, Stufano, Angela, Lovreglio, Piero, Chironna, Maria
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 18.11.2021
MDPI
Subjects
Online AccessGet full text
ISSN2076-393X
2076-393X
DOI10.3390/vaccines9111354

Cover

Loading…
Abstract Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.
AbstractList Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.
Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group ( p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55–3.72) for symptomatic infection and 2.66 (95% CI, 1.76–3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.
Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55-3.72) for symptomatic infection and 2.66 (95% CI, 1.76-3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of Southern Italy were assessed. Two cohorts of positive patients were compared. The Alpha group consisted of 11,135 subjects diagnosed between 21 March and 21 April 2021, and the Delta group consisted of 499 positive subjects diagnosed between 21 July and 21 August 2021. A descriptive and statistical analysis of the demographic and clinical characteristics of the two groups was performed. The proportion of patients with mild and moderate infections was significantly higher in the Delta than in the Alpha group (p < 0.001). In fully vaccinated patients, the proportion of symptomatic individuals was significantly higher in the Delta than in the Alpha group. The Delta group showed odds ratios of 3.08 (95% CI, 2.55-3.72) for symptomatic infection and 2.66 (95% CI, 1.76-3.94) for hospitalization. Improving COVID-19 vaccination rates is a priority, since infection with the SARS-CoV-2 Delta variant has a significant impact on patient outcomes. Additional targeted prevention strategies such as social distancing, the use of masks in indoor settings irrespective of vaccination status, and the use of a sanitary passport could be crucial to contain further spread of SARS-CoV-2 infection.
Author Lovreglio, Piero
Sallustio, Anna
Loconsole, Daniela
Stufano, Angela
Campanella, Silvia
Accogli, Marisa
Morcavallo, Caterina
Chironna, Maria
Centrone, Francesca
Peccarisi, Davide
AuthorAffiliation 2 Hygiene Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy; annasallustio@libero.it
1 Department of Biomedical Sciences and Human Oncology-Hygiene Section, School of Medicine, University of Bari, 70124 Bari, Italy; daniela.loconsole@uniba.it (D.L.); francesca.centrone.fc@gmail.com (F.C.); caterinamorcavallo@gmail.com (C.M.); campanella.silvia@libero.it (S.C.); accoisa@gmail.com (M.A.); davidepec@libero.it (D.P.)
3 Interdisciplinary Department of Medicine-Section of Occupational Medicine, School of Medicine, University of Bari, 70124 Bari, Italy; angela.stufano@uniba.it (A.S.); piero.lovreglio@uniba.it (P.L.)
AuthorAffiliation_xml – name: 3 Interdisciplinary Department of Medicine-Section of Occupational Medicine, School of Medicine, University of Bari, 70124 Bari, Italy; angela.stufano@uniba.it (A.S.); piero.lovreglio@uniba.it (P.L.)
– name: 2 Hygiene Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy; annasallustio@libero.it
– name: 1 Department of Biomedical Sciences and Human Oncology-Hygiene Section, School of Medicine, University of Bari, 70124 Bari, Italy; daniela.loconsole@uniba.it (D.L.); francesca.centrone.fc@gmail.com (F.C.); caterinamorcavallo@gmail.com (C.M.); campanella.silvia@libero.it (S.C.); accoisa@gmail.com (M.A.); davidepec@libero.it (D.P.)
Author_xml – sequence: 1
  givenname: Daniela
  orcidid: 0000-0003-2057-9745
  surname: Loconsole
  fullname: Loconsole, Daniela
– sequence: 2
  givenname: Francesca
  orcidid: 0000-0003-3018-5408
  surname: Centrone
  fullname: Centrone, Francesca
– sequence: 3
  givenname: Caterina
  orcidid: 0000-0002-9145-503X
  surname: Morcavallo
  fullname: Morcavallo, Caterina
– sequence: 4
  givenname: Silvia
  orcidid: 0000-0002-6106-6471
  surname: Campanella
  fullname: Campanella, Silvia
– sequence: 5
  givenname: Marisa
  surname: Accogli
  fullname: Accogli, Marisa
– sequence: 6
  givenname: Anna
  surname: Sallustio
  fullname: Sallustio, Anna
– sequence: 7
  givenname: Davide
  surname: Peccarisi
  fullname: Peccarisi, Davide
– sequence: 8
  givenname: Angela
  orcidid: 0000-0002-9101-7742
  surname: Stufano
  fullname: Stufano, Angela
– sequence: 9
  givenname: Piero
  orcidid: 0000-0002-1609-9397
  surname: Lovreglio
  fullname: Lovreglio, Piero
– sequence: 10
  givenname: Maria
  orcidid: 0000-0002-1043-1256
  surname: Chironna
  fullname: Chironna, Maria
BookMark eNp1kk1vEzEQhleoiJbSM1dLXNrDpv5ar5cDUthSiFSpEoGImzXr9SaONnawvUX9GfxjNk2QaCR8sTXzzjMfntfZifPOZNlbgieMVfj6AbS2zsSKEMIK_iI7o7gUOavYj5N_3qfZRYxrPJ6KMCnKV9kp45IVVBZn2e96BW5p3RLdGkhDMBH5DtX3i9lNTqr3aHQH0MkEG5PVT86Z64xO1ruIftm0Qmll0Hz6dZ7XfpFTdGP6BOjy44RMBCkn9AqBa9G0364OVjIpr9ACggWXIrIOzf0wMoJDswT945vsZQd9NBeH-zz7fvvpW_0lv7v_PKund7nmgqeclkw2WJa4AdpQbsrSUGi45BJT0XaUFsLQTsuWFU0jO6E70TIqeGnGQfCGs_Nstue2HtZqG-wGwqPyYNWTwYelgjD23BulOwlYYl2QpuAtI9Bh3VAAwTQtyqoYWR_2rO3QbEyrjUsB-mfQ5x5nV2rpH5QUlEtRjYDLAyD4n4OJSW1s1KbvwRk_REUF5pgUku_qfnckXfshuHFUOxUl1TiBXUXFXqWDjzGYTmmbYPdrY37bK4LVbofU0Q6NcddHcX-b-F_EH8Dgx5k
CitedBy_id crossref_primary_10_3390_jcm11185442
crossref_primary_10_3390_microorganisms12040720
crossref_primary_10_1016_j_rmr_2023_09_005
crossref_primary_10_1002_mef2_70004
crossref_primary_10_3390_vaccines10091546
crossref_primary_10_22625_2072_6732_2024_16_3_45_55
crossref_primary_10_52589_AJBMR_IFNRHEKO
crossref_primary_10_3390_vaccines10122172
crossref_primary_10_1080_23744235_2023_2232445
crossref_primary_10_2478_amb_2023_0014
crossref_primary_10_1002_adhm_202304575
crossref_primary_10_1016_j_cmi_2022_06_026
crossref_primary_10_1186_s42269_022_00825_w
crossref_primary_10_58854_jicm_1247409
crossref_primary_10_1111_jebm_12465
crossref_primary_10_1155_2022_4838009
crossref_primary_10_2185_jjrm_71_101
crossref_primary_10_3390_biology12091267
crossref_primary_10_3892_etm_2022_11343
Cites_doi 10.1056/NEJMoa2108891
10.1038/d41586-021-01696-3
10.1136/bmj.m4857
10.1136/bmj.n579
10.3390/microorganisms9071542
10.2807/1560-7917.ES.2021.26.26.2100557
10.1101/2021.03.24.21254277
10.1038/s41591-021-01397-4
10.2139/ssrn.3861566
10.1016/S0140-6736(21)02276-5
10.1016/j.cell.2021.06.020
10.1056/NEJMoa2114255
10.1016/S0140-6736(21)02183-8
10.1038/s41586-021-03426-1
10.1016/S0140-6736(21)01358-1
10.3390/ijerph18094766
10.1016/S0140-6736(21)01642-1
10.1001/jama.2021.14811
10.15585/mmwr.mm7036e1
10.1128/MRA.01487-20
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines9111354
DatabaseName CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
Public Health
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_cf8a080c51b54d31af0cb2aa63c25795
PMC8624869
10_3390_vaccines9111354
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
3V.
7T7
7XB
8FD
8FK
C1K
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c464t-2738b0870ba2b24e77e2ab4848026df2256e2fc8d35bb8f6cf6d32647e0004b43
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:17:17 EDT 2025
Thu Aug 21 13:59:23 EDT 2025
Mon Jul 21 10:41:15 EDT 2025
Fri Jul 25 12:01:11 EDT 2025
Thu Apr 24 23:03:53 EDT 2025
Tue Jul 01 02:25:01 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-2738b0870ba2b24e77e2ab4848026df2256e2fc8d35bb8f6cf6d32647e0004b43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6106-6471
0000-0003-3018-5408
0000-0002-9101-7742
0000-0003-2057-9745
0000-0002-1043-1256
0000-0002-1609-9397
0000-0002-9145-503X
OpenAccessLink https://doaj.org/article/cf8a080c51b54d31af0cb2aa63c25795
PMID 34835285
PQID 2602194805
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_cf8a080c51b54d31af0cb2aa63c25795
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8624869
proquest_miscellaneous_2604015844
proquest_journals_2602194805
crossref_citationtrail_10_3390_vaccines9111354
crossref_primary_10_3390_vaccines9111354
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211118
PublicationDateYYYYMMDD 2021-11-18
PublicationDate_xml – month: 11
  year: 2021
  text: 20211118
  day: 18
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Vaccines (Basel)
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Malani (ref_19) 2021; 326
Singh (ref_27) 2021; 27
Tartof (ref_35) 2021; 398
ref_14
ref_13
ref_12
Siegel (ref_30) 2021; 70
ref_32
ref_31
Challen (ref_11) 2021; 372
Hill (ref_3) 2021; 6
Veneti (ref_17) 2021; 26
Andrews (ref_34) 2021; 385
ref_18
Sheikh (ref_16) 2021; 397
ref_39
Sonabend (ref_41) 2021; 398
ref_38
ref_15
Liu (ref_33) 2021; 184
Goldberg (ref_37) 2021; 385
ref_25
ref_24
ref_23
ref_22
ref_21
ref_20
ref_40
ref_1
Callaway (ref_28) 2021; 595
ref_2
ref_29
Wise (ref_4) 2020; 371
Shrotri (ref_36) 2021; 398
ref_9
Davies (ref_10) 2021; 593
ref_5
Loconsole (ref_8) 2021; 10
ref_7
Lustig (ref_26) 2021; 26
ref_6
References_xml – volume: 385
  start-page: 585
  year: 2021
  ident: ref_34
  article-title: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2108891
– ident: ref_5
– ident: ref_32
– ident: ref_24
– volume: 595
  start-page: 17
  year: 2021
  ident: ref_28
  article-title: Delta coronavirus variant: Scientists brace for impact
  publication-title: Nature
  doi: 10.1038/d41586-021-01696-3
– volume: 371
  start-page: m4857
  year: 2020
  ident: ref_4
  article-title: Covid-19: New coronavirus variant is identified in UK
  publication-title: BMJ.
  doi: 10.1136/bmj.m4857
– volume: 26
  start-page: 2100793
  year: 2021
  ident: ref_17
  article-title: Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
  publication-title: Euro. Surveill.
– ident: ref_39
– ident: ref_40
– volume: 372
  start-page: n579
  year: 2021
  ident: ref_11
  article-title: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.n579
– ident: ref_18
  doi: 10.3390/microorganisms9071542
– volume: 26
  start-page: 2100557
  year: 2021
  ident: ref_26
  article-title: Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
  publication-title: Euro. Surveill.
  doi: 10.2807/1560-7917.ES.2021.26.26.2100557
– ident: ref_14
– ident: ref_1
– ident: ref_23
– ident: ref_21
– ident: ref_7
  doi: 10.1101/2021.03.24.21254277
– volume: 27
  start-page: 1131
  year: 2021
  ident: ref_27
  article-title: SARS-CoV-2 variants of concern are emerging in India
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01397-4
– ident: ref_6
– ident: ref_15
  doi: 10.2139/ssrn.3861566
– ident: ref_25
– ident: ref_31
– volume: 398
  start-page: 1825
  year: 2021
  ident: ref_41
  article-title: Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: A mathematical modelling study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02276-5
– volume: 6
  start-page: 121
  year: 2021
  ident: ref_3
  article-title: Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
  publication-title: Wellcome Open Res.
– ident: ref_29
– ident: ref_2
– volume: 184
  start-page: 4220
  year: 2021
  ident: ref_33
  article-title: Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
  publication-title: Cell
  doi: 10.1016/j.cell.2021.06.020
– ident: ref_12
– volume: 385
  start-page: 1393
  year: 2021
  ident: ref_37
  article-title: Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2114255
– volume: 398
  start-page: 1407
  year: 2021
  ident: ref_35
  article-title: Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02183-8
– ident: ref_13
– ident: ref_38
– volume: 593
  start-page: 270
  year: 2021
  ident: ref_10
  article-title: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
  publication-title: Nature
  doi: 10.1038/s41586-021-03426-1
– volume: 397
  start-page: 2461
  year: 2021
  ident: ref_16
  article-title: Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01358-1
– ident: ref_9
  doi: 10.3390/ijerph18094766
– volume: 398
  start-page: 385
  year: 2021
  ident: ref_36
  article-title: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01642-1
– ident: ref_22
– ident: ref_20
– volume: 326
  start-page: 1001
  year: 2021
  ident: ref_19
  article-title: Confronting the Delta Variant of SARS-CoV-2, Summer 2021
  publication-title: JAMA
  doi: 10.1001/jama.2021.14811
– volume: 70
  start-page: 1249
  year: 2021
  ident: ref_30
  article-title: Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years—United States, August 2020–August 2021
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm7036e1
– volume: 10
  start-page: e01487-20
  year: 2021
  ident: ref_8
  article-title: Genome Sequence of a SARS-CoV-2 VUI 202012/01 Strain Identified from a Patient Returning from London, England, to the Apulia Region of Italy
  publication-title: Microbiol. Resour. Announc.
  doi: 10.1128/MRA.01487-20
SSID ssj0000913867
Score 2.255769
Snippet Differences in the demographic and clinical characteristics of patients infected with the Alpha and Delta SARS-CoV-2 variants of concern in a large region of...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1354
SubjectTerms Contact tracing
Coronaviruses
COVID-19
COVID-19 vaccine
COVID-19 vaccines
Demographics
Disease control
Disease transmission
Epidemiology
Health surveillance
Hospitalization
Immunization
Infections
Laboratories
Patients
Public health
Respiratory diseases
SARS-CoV-2 Alpha variant
SARS-CoV-2 Delta variant
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
surveillance
Vaccination
Virulence
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1da9swFBWjT3sZ-2TZunIHo7RQu9GHZXlvabrSDLaVtQ19M5IssUJRRpMU8jP2j3clu2k8GHvZqyUbWbpXOke694iQD76yeliZInM-7lZxqzKDOCErpW1oYVSpUn7Fl6_y9FJ8viquNq76ijFhrTxw23GH1iuNqMYW1BSi4VT7oTVMa8ktWluV1EtxzdsgU2kOrihXsmy1fDjy-sM7beNJ9Tw6Ny9EbxlKav09iNkPkNxYcU6ekicdVIRR28Rn5JELz8nuWas1vTqAi4fUqfkB7MLZgwr16gX5lfIGcGGCiPKWyKph5mH8bTo5zmj1EcZ9peZYOOkCs8Ic4vYsIDaE89H382w8m2YMjt3NQsPeUU5zBCQ52wcdGhjFZN32Kc3LfZgi-Y6xNXAdIN3P524DTBDir16Sy5NPF-PTrLt_IbNCikXK2jFDdGijmWHClaVj2gglFBK3xuNMIB3zVjW8MEZ5ab1sEA2K0kWkaAR_RbbCLLjXBLxnMeqqkMiuBNei4kYZQRnVilP8xoDk98NR206cPN6RcVMjSYnjV_8xfgOyt37hZ6vL8feqR3F819WioHZ6gGZWd2ZW_8vMBmT73jrqzsvnNXJBnPCxO7D4_boY_TMeuujgZstUBykswjxsR9mzql6D-iXh-kdS-o7ZO0pWb_7HH7wlj1mMx4khjGqbbC1ul-4dAqqF2Um-8xs9NB3i
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELZg-4KEEAwQhYEOCU2btHSN4zgOX1DbbVqRGNVeqn2LbMeGSVMy-oLUn8E_5i5JW4IEX2MnsXS-83Pnu-cY--BTq3upiQPnKVoVWRUYxAlBIm0exkYlqqqv-HIuz67F55v4pgm4zZq0ypVNrAx1XlqKkR8h7kblEqoXf7r_EVDXKLpdbVpoPGTbaIIV7vDtwcn5-GIdZSHWSyWTmtMnQv_-6Ke2dGM9IyWPYtE6jirW_hbUbCdK_nHynD5lTxrICP1axs_YA1fssL1xzTm9PISrTQnV7BD2YLxho17usMd1YA7qeqPn7FdVT4AHFhD6W6C3DaWH4dfJ6DgI048wbDM40-CoSdgqZkBhW0DMCJf9i8tgWE4CDsfubq5hf9ANuwhUuvwAdJFDn4p466dhNzmACTrllHMDtwVUffvctIARQv_lC3Z9enI1PAuavgyBFVLMq2oe00NFN5obLlySOK6NUCgcLnOPFkI67q3Ko9gY5aX1MkeUKBJHCNKI6CXbKsrCvWLgPadsrFii1yUiLdLIKCNCHmoVhfiNDuuuxJPZhrScemfcZei8kDyzv-TZYfvrF-5rvo5_Tx2QvNfTiGi7elBOv2WN3mbWK42g2sahiUUehdr3rOFay8iisUvjDttd7Zas0f5ZttmrHfZ-PYx6S5cxunDlopqDri3CP1xH0tplrQW1R4rb7xUDOFX1KJm-_v_P37BHnDJwKGlR7bKt-XTh3iKEmpt3jZ78Bp6WG2E
  priority: 102
  providerName: ProQuest
Title Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy
URI https://www.proquest.com/docview/2602194805
https://www.proquest.com/docview/2604015844
https://pubmed.ncbi.nlm.nih.gov/PMC8624869
https://doaj.org/article/cf8a080c51b54d31af0cb2aa63c25795
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZge-EFjZsojMpIaNqkJTS2kzhICLXdphVpo9rWqm-R7dgwqUpHL4j-DP4x57hpS9CQeLWdyPHx8fk-51wIeecyo1qZjgPr8LaKGxlowAlBmpgiirVMpY-vuLhMzgfi8ygebcsBVQs4u5faYT2pwXQc_vy-_AQK_xEZJ1D29z-UwZ_QM9RbHouHZBfMUop1HC4qrO-P5Szi0leUZcDdA57x0SrVz33vqFkpn8y_hkDr_pN_GKSzPfK4QpK0vRL9E_LAlk_JQX-Vinp5TG-2kVWzY3pA-9sk1ctn5JcPKwC7RREELoB004mj3S_D3kkQZR9ot57IGTt7ld9WOaN4e0sBOtLr9tV10J0MA0ZP7Hiu6GEnjELAKyE7oqosaBtjeVetUZge0SFwc3S9obcl9eX77LSkPVj85XMyODu96Z4HVXmGwIhEzH1Qj26BvmvFNBM2TS1TWkghgdcVDg6KxDJnZMFjraVLjEsKAIsitQgkteAvyE45Ke1LQp1j6JQVJ0C-BFci41pqEbFISR7BOxokXIsjN1XuciyhMc6Bw6D88r_k1yCHmwfuVmk7_j20g_LdDMN8275hMv2aV-qbGycVYGsTRzoWBY-UaxnNlEq4gTMvixtkf7078vUezoEqgj2A5YDut5tuUF_8J6NKO1n4McBwAQXCPNLarqpNqN5T3n7zicAxuEcm2av__9jX5BFDpxz0Y5T7ZGc-Xdg3gKrmukl2O6eX_aumv5Voet35DTVtIdM
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wASQjBAKxtgJJg2aeka23EcJIR62dSyrVRbV-0t2I7DJk3JaFpQfwZ_hN_IcZK2BAne9mo7jqVz8XeOzwWht3GgZTNQnmNi662iWjgKcILjcx25nhK-yPMrTge8d8E-XXqXa-jXIhfGhlUudGKuqKNUWx_5AeBuEC4mmt7H22-O7RplX1cXLTQKtjg28x9gsmUf-l2g7ztCjg5HnZ5TdhVwNONsmueiqCawqZJEEWZ83xCpmICtCY9i4G9uSKxFRD2lRMx1zCPAOMw3Fv8oRmHfe2idUYAKNbTePhwMz5ZeHVtlU3C_qCFEadA8-C61fSHPrFKhHqtcf3mXgAq0rQZm_nHTHT1Gj0qIilsFTz1BaybZQDvDosb1fB-PVilb2T7ewcNV9ev5BnpYOAJxkd_0FP3M8xfggsQWbc7AusdpjDufx_2u4wbvcadaMdpO9ssAsSTD1k2MAaPi89bZudNJxw7BXXMzlXi33XAbAIwaZA_LJMItmzRcjLoNfw-PJYhWMs3wdYLzPoFmkuA-mBrzZ-jiTij2HNWSNDGbCMcxsdFfHgcrj1HJAqqEYi5xpaAu7FFHjQV5Ql0WSbe9Om5CMJYsPcO_6FlHu8sPbov6IP9e2rb0Xi6zhb3zgXTyNSz1RKhjIQHEa89VHouoK-OmVkRKTjUo18Cro-0Ft4SltsnClWzU0ZvlNOgJ-_gjE5PO8jVgSgPchHP4FS6rHKg6k1xf5RXHbRaR4MGL___8NbrfG52ehCf9wfEWekBs9I8NmBTbqDadzMxLgG9T9aqUGYy-3LWY_gZ6c1c2
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyEkhGCAVhhgJJg2aWkbx0kcJIR6WbUyKNUu1d6C7dgwaUpGL6D-DP4Ov45zkrQlSPC2V9uxI52Lv3N8LoS8spGWrUj5jrHorfK0cBTgBCcMdOL6SoQiz6_4OAyOzvn7C_9ig_xa5sJgWOVSJ-aKOsk0-sibgLtBuLho-U1bhkWMev13198c7CCFL63LdhoFixybxQ8w36ZvBz2g9WvG-odn3SOn7DDgaB7wWZ6XolrAskoyxbgJQ8Ok4gKOYUFigdcDw6wWiecrJWygbZAA3uGhQSykuAf73iKbIaaP1shm53A4Oll5eLDipgjCop6Q50Wt5nep8bV8igrG83nlKsw7BlRgbjVI849br3-f3CvhKm0X_PWAbJh0i-yOinrXiwN6tk7fmh7QXTpaV8JebJG7hVOQFrlOD8nPPJcBLkuKyHMOlj7NLO1-Gg96jhu9od1q9WicHJTBYumUosuYAl6lp-2TU6ebjR1Ge-ZqJulep-E2ACQ12D6VaULbmEBcjLqNcJ-OJYhZOpvSy5TmPQPNJKUDMDsWj8j5jVDsMamlWWq2CbWWYSSYH4DFxz3JI08JxV3mSuG5sEedNJbkiXVZMB37dlzFYDghPeO_6Fkne6sProtaIf9e2kF6r5Zhke98IJt8iUudEWsrJAB67bvK54nnStvSikkZeBoUbeTXyc6SW-JS80zjtZzUycvVNOgMfAiSqcnm-RowqwF6wn-EFS6r_FB1Jr38mlcfx4wiEURP_n_4C3IbxDP-MBgePyV3GAYCYeyk2CG12WRungGSm6nnpchQ8vmmpfQ3nqhbdA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changing+Features+of+COVID-19%3A+Characteristics+of+Infections+with+the+SARS-CoV-2+Delta+%28B.1.617.2%29+and+Alpha+%28B.1.1.7%29+Variants+in+Southern+Italy&rft.jtitle=Vaccines+%28Basel%29&rft.au=Loconsole%2C+Daniela&rft.au=Centrone%2C+Francesca&rft.au=Morcavallo%2C+Caterina&rft.au=Campanella%2C+Silvia&rft.date=2021-11-18&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=11&rft.spage=1354&rft_id=info:doi/10.3390%2Fvaccines9111354&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines9111354
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon